Previous close | 1.9150 |
Open | 1.9300 |
Bid | 1.7200 x 300 |
Ask | 1.7800 x 100 |
Day's range | 1.6200 - 1.9899 |
52-week range | 1.3030 - 4.8900 |
Volume | |
Avg. volume | 295,877 |
Market cap | 84.639M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Q4 2023 Cue Biopharma Inc Earnings Call